Nls Pharmaceutics Ltd (NLSP)

May 01, 2025

NLS Pharmaceutics Delays Yearly Report Filing - TipRanks

May 01, 2025

Apr 26, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 26, 2025

Apr 24, 2025

NLS Pharmaceutics Announces Board Resignation Amid Restructuring Efforts - TipRanks

Apr 24, 2025

Apr 18, 2025

Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics (PR Newswire) - Aktiellt

Apr 18, 2025

Apr 18, 2025

Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS (PR Newswire) - Aktiellt

Apr 18, 2025

Apr 16, 2025

NLS and Kadimastem: Swiss-israeli merger in ALS - European Biotechnology Magazine

Apr 16, 2025

Apr 15, 2025

NLS Pharmaceutics Study Suggests Mazindol May Help Treat Fentanyl Use Disorder - marketscreener.com

Apr 15, 2025

Apr 15, 2025

NLS Pharmaceutics (NLSP): Promising Preclinical Results for Mazi - GuruFocus

Apr 15, 2025

Apr 15, 2025

NLS Pharmaceutics Reports Positive Results in Fentanyl Study - TipRanks

Apr 15, 2025

Apr 15, 2025

Nls Pharmaceutics Announces Positive Results From Study Ko-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward In Animal Models - MarketScreener

Apr 15, 2025

Apr 15, 2025

NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models - Quantisnow

Apr 15, 2025

Apr 15, 2025

NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models (PR Newswire) - Aktiellt

Apr 15, 2025

Apr 14, 2025

Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics - ADVFN

Apr 14, 2025

Apr 06, 2025

NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest - ACCESS Newswire

Apr 06, 2025

Apr 03, 2025

NLSP Stock Touches 52-Week Low at $1.73 Amid Steep Annual Decline - MSN

Apr 03, 2025

Apr 02, 2025

Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements - ACCESS Newswire

Apr 02, 2025

Mar 31, 2025

What's Going On With NLS Pharmaceutics Shares Monday? - Benzinga

Mar 31, 2025

Mar 31, 2025

NLS Pharmaceutics Secures $3 Million Financing and $25 Million Equity Facility - TipRanks

Mar 31, 2025

Mar 31, 2025

NLS Pharmaceutics secures $2M for Kadimastem merger - Investing.com

Mar 31, 2025

Mar 31, 2025

NLS Pharmaceutics secures $2M for Kadimastem merger By Investing.com - Investing.com Canada

Mar 31, 2025

Mar 31, 2025

NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement - StreetInsider

Mar 31, 2025

Mar 25, 2025

NLSP stock touches 52-week low at $1.47 amid market challenges By Investing.com - Investing.com South Africa

Mar 25, 2025

Mar 25, 2025

NLSP stock touches 52-week low at $1.47 amid market challenges - Investing.com India

Mar 25, 2025

Mar 16, 2025

NLS Pharmaceutics Ltd. (NASDAQ:NLSPW) Short Interest Down 31.6% in February - Defense World

Mar 16, 2025

Mar 10, 2025

NLS Pharmaceutics announces merger with Kadimastem By Investing.com - Investing.com Canada

Mar 10, 2025

Mar 10, 2025

NLS Pharmaceutics Announces Strategic Merger and Advances in Therapeutic Pipeline - TipRanks

Mar 10, 2025

Mar 10, 2025

NLS Pharmaceutics CEO Issues Letter to Shareholders - Quantisnow

Mar 10, 2025

Mar 10, 2025

NLS Pharmaceutics announces merger with Kadimastem - Investing.com India

Mar 10, 2025

Mar 05, 2025

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger - Marketscreener.com

Mar 05, 2025

Mar 04, 2025

NLSP stock touches 52-week low at $1.71 amid steep annual decline - Investing.com

Mar 04, 2025

Mar 04, 2025

NLSP stock touches 52-week low at $1.71 amid steep annual decline By Investing.com - Investing.com South Africa

Mar 04, 2025

Mar 01, 2025

NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from Nasdaq - ACCESS Newswire

Mar 01, 2025

Feb 28, 2025

NLS Pharmaceutics Announces Compliance with Nasdaq Bid Price Requirement - ACCESS Newswire

Feb 28, 2025

Feb 28, 2025

AEX-2 increases total wake duration in mouse model - BioWorld Online

Feb 28, 2025

Feb 27, 2025

NLS Pharmaceutics Announces $20 Million Standby Equity Distribution Agreement and $2.5 Million Equity Investment - ACCESS Newswire

Feb 27, 2025

Feb 27, 2025

NLS Pharmaceutics reports progress in narcolepsy treatment By Investing.com - Investing.com South Africa

Feb 27, 2025

Feb 27, 2025

NLS Pharmaceutics reports progress in narcolepsy treatment - Investing.com

Feb 27, 2025

Feb 27, 2025

Can NLS Pharmaceutics' Orexin Agonist Treat More Than Just Sleep Disorders? New Data Says Yes - StockTitan

Feb 27, 2025

Feb 25, 2025

NLS Pharmaceutics and Partners Achieve Milestone in Diabetes Treatment Development - MSN

Feb 25, 2025

Feb 25, 2025

Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment - PR Newswire

Feb 25, 2025

Feb 19, 2025

NLS Pharmaceutics Announces Notice of Allowance for U.S. Patent Covering Mazindol for Opioid Dependence and Substance Use Disorder - ACCESS Newswire

Feb 19, 2025

Feb 11, 2025

NLS Pharmaceutics And Kadimastem Unveil Multi-Target Diabetes Approach - Nasdaq

Feb 11, 2025

Feb 10, 2025

Is NLSP’s price to cash per share ratio a concern for investors? - US Post News

Feb 10, 2025

Feb 10, 2025

NLS Pharmaceutics Ltd’s Shares Reel: -37.16% Quarterly Revenue Decline Amid 6.35M Market Cap - The InvestChronicle

Feb 10, 2025

Feb 10, 2025

NLS Pharmaceutics Ltd (NLSP) Shares Rise Despite Market Challenges - The News Heater

Feb 10, 2025